Emerging treatments in the management of psoriasis: biological targeting with ustekinumab

References

• PrinzJThe role of T cells in psoriasisJ Eur Acad Dermatol Venereol20031725727012702062
   PubMed Web of Science ®Google Scholar
• ChristophersEPsoriasis – epidemiology and clinical spectrumClin Exp Dermatol20012631432011422182
   PubMed Web of Science ®Google Scholar
• LebwohlMPsoriasisLancet20033611197120412686053
   PubMed Web of Science ®Google Scholar
• SchonMPBoehnckeWHPsoriasisN Engl J Med20053521899191215872205
   PubMed Web of Science ®Google Scholar
• GladmanDDBrockbankJPsoriatic arthritisExpert Opin Investig Drugs2000915111522
   PubMed Web of Science ®Google Scholar
• CroffordLJKlippelJHPsoriatic ArthritisPrimer on the rheumatic diseases12th editionAtlanta (GA)Arthritis Foundation2001234238
   Google Scholar
• GladmanDDShuckettRRusselMLPsoriatic arthritis (PSA): an analysis of 220 patientsQ J Med1987621271413659255
   PubMedGoogle Scholar
• de ArrudaLHDe MoracsAPThe impact of psoriasis in quality of lifeBr J Dermatol2001144 Suppl 58333611501512
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol19994140140710459113
   PubMed Web of Science ®Google Scholar
• EspositoMSaracenoRGiuntaAAn Italian study on psoriasis and depressionDermatology200621212312716484818
   PubMed Web of Science ®Google Scholar
• GuptaMAGuptaAKDepression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasisBr J Dermatol19981398468509892952
   PubMed Web of Science ®Google Scholar
• GuptaMASchorkNJGuptaAKSuicidal ideation in psoriasisInt J Dermatol1993321881908444530
   PubMed Web of Science ®Google Scholar
• PearceDJMorrisonAEHigginsKBThe comorbid state of psoriasis patients in a university dermatology practiceJ Dermatolog Treat2005165–631932316428152
   PubMed Web of Science ®Google Scholar
• Tristani-FirouziPKruegerGGEfficacy and safety of treatment modalities for psoriasisCutis19986111219787987
   PubMed Web of Science ®Google Scholar
• AshcroftDMLi Wan PoAGriffithsCETherapeutic strategies for psoriasisJ Clin Pharm Ther20002511010771459
   PubMed Web of Science ®Google Scholar
• SterryWBarkerJBoehnckeWHBiologicals in psoriasis consensusBr J Dermatol2004151 Suppl 6931715265063
   PubMed Web of Science ®Google Scholar
• LandeRGregorioJFacchinettiVPlasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptideNature2007449716256456917873860
   PubMed Web of Science ®Google Scholar
• LowesMAKikuchiTFuentes-DuculanJPsoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cellsJ Invest Dermatol200812851207121118200064
   PubMed Web of Science ®Google Scholar
• da SilvaAJBrickelmaierMMajeauGRAlefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cellsJ Immunol20021684462447111970990
   PubMed Web of Science ®Google Scholar
• PiascikPAlefacept, first biologic agent approved for treatment of psoriasisJ Am Pharm Assoc200343649650
   Google Scholar
• KruegerGGPappKAStoughDBA randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol20024782183312451365
   PubMed Web of Science ®Google Scholar
• LebwohlMChristophersELangleyRAn international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol200313971972712810502
   PubMed Web of Science ®Google Scholar
• JullienDPrinzJCLangleyRGT-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of actionDermatology2004208429730615178911
   PubMed Web of Science ®Google Scholar
• RaptivaProduct information Available at: http//www.kompendium.ch
   Google Scholar
• Raptiva EMEA approved product information Available at: http://www.emea.com
   Google Scholar
• GuptaAKChermanAMEfalizumab in the treatment of psoriasisJ Cutan Med Surg200610576817241576
   PubMed Web of Science ®Google Scholar
• WoolacottNHawkinsNMasonAEtanercept and efalizumab for the treatment of psoriasis: a systematic reviewHealth Technol Assess200610125217083854
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA)European Public Assessment Report on Enbrel Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-PI-en.pdfAccessed July 31, 2007
   Google Scholar
• MeasePPsoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanerceptClin Exp Rheumatol200220 6 Suppl 2811612111892698
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTEtanercept as monotherapy in patients with psoriasisN Engl J Med20033492014202214627786
   PubMed Web of Science ®Google Scholar
• GottliebABMathesonRTLoweNA randomized trial of etanercept as monotherapy for psoriasisArch Dermatol20031391627163214676082
   PubMed Web of Science ®Google Scholar
• PappKATyringSLahfaMA global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBr J Dermatol20051521304131215948997
   PubMed Web of Science ®Google Scholar
• TyringSGottliebAPappKEtanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trialLancet2006367293516399150
   PubMed Web of Science ®Google Scholar
• ZhouHClinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion proteinJ Clin Pharmacol20054549040715831771
   PubMed Web of Science ®Google Scholar
• NestorovIZitnikRLuddenTPopulation pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasisJ Pharmacokinet Pharmacodyn20043146349016222785
   PubMed Web of Science ®Google Scholar
• GottliebABEvansRLiSInfliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialJ Am Acad Dermatol20045153454215389187
   PubMed Web of Science ®Google Scholar
• OhCJDasKMGottliebABTreatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJ Am Acad Dermatol200042 5 Pt 182983010775863
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappKInfliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialLancet20053661367137416226614
   PubMed Web of Science ®Google Scholar
• MenterAFeldmanSRWeinsteinGDA randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJ Am Acad Dermatol200756311517097378
   PubMed Web of Science ®Google Scholar
• SalfeldJKaymakcalanZTraccyDGeneration of fully human anti- TNF antibody D2E7 [abstract]Arthritis Rheum199841Suppl 57
   Google Scholar
• Humira [package insert]. Abbott Park, Ill. Abbott
   Google Scholar
• MeasePGladmanDRitchlinCAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritisArthritis Rheum200552103279328916200601
   PubMed Web of Science ®Google Scholar
• GladmanDMeasePRitchlinCAdalimumab for long-term treatment of psoriatic arthritis. Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trialsArthritis Rheum200756247648817265483
   PubMed Web of Science ®Google Scholar
• GordonKBLangleyRGLeonardiCClinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyJ Am Acad Dermatol20065559860617010738
   PubMed Web of Science ®Google Scholar
• MenterATyringSGordonKAdalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trialJ Am Acad Dermatol200858110611517936411
   PubMed Web of Science ®Google Scholar
• SauratJHStinglGDubertretLEfficacy and safety results from the comparative study of adalimumab (Humira) versus methotrexate versus placebo in psoriasis patients (CHAMPION)Br J Dermatol2008158355856618047523
   PubMed Web of Science ®Google Scholar
• DuerrRHTaylorKDBrantSRA genome-wide association study identifies IL23R as an inflammatory bowel disease geneScience20063141461146317068223
   PubMed Web of Science ®Google Scholar
• CaponFDi MeglioPSzaubJSequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisHum Genet20071222010617587057
   PubMed Web of Science ®Google Scholar
• PiskinGSylva-SteenlandRMRBosJDTeunissenMBMIn vitro and in situ expression of IL-23 by psoriasis lesions: enhanced expression in psoriatic skinJ Immunol20061761908191516424222
   PubMed Web of Science ®Google Scholar
• TortiDCFeldmanSRInterleukin-12, interleukin-23, and psoriasis: current prospectsJ Am Acad Dermatol2007571059106817706835
   PubMed Web of Science ®Google Scholar
• TrinchieriGInterleukin-12 and the regulation of innate resistance and adaptive immunityNat Rev Immunol2003313314612563297
   PubMed Web of Science ®Google Scholar
• KruegerJGThe immunologic basis for the treatment of psoriasis with new biologic agentsJ Am Acad Dermatol20024612311756941
   PubMed Web of Science ®Google Scholar
• ToichiETorresGMcCormicSAn anti-IL-12p40 antibody down-regulates Type 1 cytokines, chemokines and IL-12/IL23 in psoriasisJ Immunol200617774917492616982934
   PubMed Web of Science ®Google Scholar
• WilsonNJBonifaceKChanJRDevelopment, cytokine profile and function of human interleukin 17-producing helper T cellsNat Immunol200789505717676044
   PubMed Web of Science ®Google Scholar
• Bruch-GerharzDFehselKSuschekCMichelGRuzickaTKolb-BachofenVA proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytesJ Exp Med19961842007128920887
   PubMed Web of Science ®Google Scholar
• NickoloffBJCracking the cytokine code in psoriasisNat Med20071324224417342112
   PubMed Web of Science ®Google Scholar
• Vanden EijndenSGorielySDe WitDWillemsFGoldmanMIL-23 upregulates IL-10 and induces IL-17 synthesis by polyclonally activated naïve T cells in humanEur J Immunol2005354697515682457
   PubMed Web of Science ®Google Scholar
• ZhengYDanilenkoDMValdezPInterleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosisNature20074456485117187052
   PubMed Web of Science ®Google Scholar
• NestleFOConradCThe IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasisJ Invest Dermatol2004123XIVXV15610500
   PubMed Web of Science ®Google Scholar
• KauffmanCLAriaNToichiEA phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisJ Invest Dermatol200412361037104415610511
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGLeonardiCA human interleukin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med20073565809217287478
   PubMed Web of Science ®Google Scholar
• KimballAGordonKBLangleyRGSafety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialArch Dermatol200814420020718283176
   PubMed Web of Science ®Google Scholar
• LeonardiCKimballABPappKEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711165117418395577
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• SternRSNijstenTFeldmanSRMargolisDJRolstadTPsoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfactionJ Invest Dermatol Symp Proc2004913639
   PubMed Web of Science ®Google Scholar
• RichardsHLFortuneDGGriffithsCEAdherence to treatment in patients with psoriasisJ Eur Acad Dermatol Venereol20062037037916643132
   PubMed Web of Science ®Google Scholar